Abstract 4761: Transcriptomic overview of EML4-ALK lung cancer cells resistant to ALK inhibitors highlights a vulnerability to CDK inhibitors

Volume: 79, Issue: 13_Supplement, Pages: 4761 - 4761
Published: Jul 1, 2019
Abstract
Introduction: EML4-ALK-driven lung cancer represents about 5% of lung adenocarcinomas. Despite the constant expansion of the armamentarium to inhibit ALK, patients typically develop acquired resistance to ALK inhibitors. In the case of resistance mediated by ALK mutations, sequencing of ALK inhibitors is recommended, but in ALK wild-type patients, a better understanding of acquired resistance, as well as new therapeutic strategies are needed....
Paper Details
Title
Abstract 4761: Transcriptomic overview of EML4-ALK lung cancer cells resistant to ALK inhibitors highlights a vulnerability to CDK inhibitors
Published Date
Jul 1, 2019
Volume
79
Issue
13_Supplement
Pages
4761 - 4761
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.